
Dry Eye Syndrome drug candidate shows promise
BRIM Biotechnology has announced it is preparing to initiate Phase III trials in 2022 for BRIM421. BRIM421 is a first-in-class peptide derived from BRIM’s proprietary, stem cell regenerative, Short Peptide (PDSP) technology platform, which can also be applied across multiple therapy areas and indications. Data demonstrate the drug has the… Read More















